- Advertisement -
Perth-based biopharmaceutical company Zelira Therapeutics (ASX: ZLD) has secured US$33 million (A$49 million) in funding after its HOPE 1 special purpose vehicle (SPV) signed a deal with ThirdGate Capital’s TGC Biotechnology Fund.
Launched in October 2020 in Australia, HOPE 1 is a medicinal…
Click here to view the original article.
